CURRICULUM VITAE. Name: Christopher Ryan Heery, M.D.

Transcription

1 CURRICULUM VITAE Name: Christopher Ryan Heery, M.D. Education: 2000 B.A. (English), Duke University, Durham, NC Minor: History 2006 M.D., East Carolina University, Brody School of Medicine, Greenville, NC Employment Intern, Department of Internal Medicine, Baystate Medical Center, Springfield, MA Resident, Department of Internal Medicine, University of Illinois- Chicago, Chicago, IL 2009-April 2012 Clinical Fellow, Medical Oncology Branch, National Cancer Institute, Bethesda, MD April 2012-present Staff Clinician, Laboratory of Tumor Immunology and Biology and Medical Oncology Branch, National Cancer Institute, Bethesda, MD Nov present Director, Clinical Trials Group, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD Medical Licenses and Certifications: Medical license: State of Illinois 2008-present Diplomate, National Board of Medical Examiners, 2007 Diplomate, Internal Medicine, American Board of Internal Medicine, 2009 Board Certified Medical Oncology, 2011 Advanced Cardiac Life Support, Basic Cardiac Life Support, 2006-present Recent Honors and Other Special Scientific Recognition: 2011 Merit Award, American Society of Clinical Oncology 2012 Merit Award, American Society of Clinical Oncology Research Interests: Cancer immunotherapy: translational clinical trials Colorectal Cancer Prostate Cancer Chordoma BIBLIOGRAPHY Published 1. Affronti, ML, Heery, CR, Herndon, JE, Rich, JN, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Friedman, AH, Bigner, DD, Friedman, HS. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 1;115(15): , Heery, CR, Madan, RA. Modern Immunotherapy for the treatment of prostate cancer. Drug Discov Today: Therapeutic Strategies (2011), doi: /j.ddstr

2 3. Bilusic, M, Heery, C, Madan, RA. Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. Vaccine 29(38): , Mohebtash, M, Tsang, K, Madan, RA, Huen, N, Poole, DJ, Jochems, C, Jones, J, Ferrara, T, Heery, CR, Arlen, PM, Pazdur, M, Rauckhorst, M, Jones, EC, Dahut, WL, Schlom, J, Gulley, JL. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 17(22): , Heery CR, Engelhard HH, Slavin KV, Michals EA, Villano JL, Unusual CNS presentation of thyroid cancer. Clinical Neurology and Neurosurgery 114(7):1107-9, Madan, RA, Bilusic, M, Heery, C, Schlom, J, Gulley, JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Seminars in Oncology Jun; 39(3): Madan, RA, Heery, CR, Gulley, JL. Combination of vaccine and immune checkpoint inhibitor safe with encouraging clinical activity. OncoImmunology 1(7): , Kim, JW, Bilusic, M, Heery, CR, Madan, RA. Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers 4(4), , Heery, CR, Hodge, JW, Gulley, JL. Combining radiation and therapeutic cancer vaccines: a synergistic approach. Breast Cancer Manage. 1(4), 1-11, Gulley, JL, Heery, CR, Madan, RA, Walter, BA, Merino, MJ, Vergati, M, Poole, DJ, Cereda, V, Tsang, K, Dahut, WL, Schlom, J, Pinto, PA. A phase I study of intraprostatic administration of PSA-TRICOM vaccine in men with locally recurrent or progressive prostate cancer, Cancer Immunol Immunother. 62(9): , Gulley, JL, Madan, RA, Heery, CR. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer. Am Soc Clin Oncol Educ Book , Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J. Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. Cancer Immunol Res Feb;2(2): Bilusic, M, Heery, CR, Arlen, PM, Rauckhorst, M, Apelian, D, Tucker, JA, Jochems, C, Schlom, J, Gulley, JL, Madan, RA. Phase I trial of a recombinant yeast-cea vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother. 63(3):225-34, Madan RA, Heery CR, Gulley JL. Poxviral-based vaccine elicits immunologic responses in cancer patients. Oncoimmunology 2014 Apr 29;3:e Farsaci, B, Jochems, C, Grenga, I, Donahue, RN, Tucker, JA, Pinto, PA, Merino, MJ, Heery, CR, Madan, RA, Gulley, JL, Schlom, J. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the 2

3 absence of modifications of PBMC immune cell subsets. Int J Cancer Aug 15;135(4): Pending Publications: 1. Heery CR*, Rajan A*, O Sullivan G, Thomas A, Guha U, Berman A, Carter CA, Szabo E, Brzezniak C, Madan R, Ballester L, Pittaluga S, Farsaci B, Lepone LM, Sabzevari H, Chen K, Schlom J, Gulley JL, Hassan R. Anti-PD-L1 Antibody Treatment of Malignant Thymoma. Submitted. 2. Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Madan RA, Bilusic M, Kim JW, McMahon S, Steinberg SM, Hodge JW, Schlom J, Gulley JL. A phase 2 randomized trial of docetaxel (DOC) alone or in combination with therapeutic cancer vaccine, CEA-, MUC-1-TRICOM (PANVAC). Manuscript in process. Clinical Protocols (Active): Principal investigator: NCI 14-C-0142 An open-label phase I study to evaluate the safety and tolerability of a modified vaccinia Ankara (MVA)-based vaccine modified to express brachyury and T-cell costimulatory molecules (MVA-brachyury-TRICOM) Lead Associate Investigator: NCI 13-C-0063 A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB C, a monoclonal anti-pd-l1 antibody, in subjects with metastatic or locally advanced solid tumors and expansion to selected indications Lead Associate Investigator: NCI 11-C-0225 First in-human phase I trial of NHS-IL12 in subjects with metastatic solid tumors Associate Investigator: NCI 13-C-0153 A Phase II Trial of Enzalutamide in Combination with PSA-TRICOM in Patients with Non-metastatic Castration Sensitive Prostate Cancer Associate Investigator: NCI 13-C-0146 A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men with Metastatic Castration Resistant Prostate Cancer Associate Investigator: NCI 13-C-0095 A Phase 2 study of GI-6207 in patients with recurrent medullary thyroid cancer Associate Investigator: NCI 11-C-0262-D A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer Associate Investigator: NCI 11-C-0247 A randomized phase II study of L-BLP25 in combination with standard androgen deprivation therapy and radiation therapy for newly diagnosed, high risk prostate cancer patients. Associate Investigator: NCI 11-C-0242 Collection of Blood from Patients with Cancer for Analysis of Genetic Differences in Drug Disposition Associate Investigator: NCI 04-C-0274 Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or other immunotherapeutic agents 3

4 Associate Investigator: NCI 02-C-0179 Collection of Blood, Tissue and Urine from Patients with Cancer Clinical Protocols (Completed): Lead Associate Investigator: NCI 12-C-0056An open label phase I study to evaluate the safety and tolerability of GI-6301 a vaccine consisting of whole, heat-killed recombinant Saccharomyces cerevisiae (yeast) genetically modified to express Brachyury protein in adults with metastatic carcinoma Associate Investigator: NCI 09-C-0101 An open label phase I study to evaluate the safety and tolerability of a vaccine (GI-6207) consisting of whole, heat-killed recombinant Saccharomyces cerevisiae (yeast) genetically modified to express CEA protein in adults with metastatic CEAexpressing carcinoma. Associate Investigator: NCI 07-C-0107 A randomized phase II trial combining vaccine therapy with PROSTVAC/TRICOM and flutamide vs. flutamide alone in patients with androgeninsensitive, nonmetastatic (D0.5) prostate cancer. Associate Investigator: NCI 07-C-0106 A randomized phase 2.5 study of 153Sm-EDTMP (Quadramet) with or without a PSA/TRICOM vaccine in men with androgen-insensitive metastatic prostate cancer. Associate Investigator: NCI 05-C-0229 A randomized pilot phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer. Associate Investigator: NCI 04-C-0246 An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC(TM)-V (Vaccinia) and PANVAC (TM)-F (Fowlpox) in Combination with Sargramostim in Adults with Metastatic Carcinoma Book chapters: Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Madan RA, Heery CR, Gulley JL. Chapter Two Therapeutic Cancer Vaccines. Advances in Cancer Research. Volume 121, 2014:pages Heery CR and Gulley JL. Nuts and Bolts of Cancer Immunothearpy. Cancer Consult: Expertise for Clinical Practice. June 2014 Heery CR and Kreisl T. Central Nervous System Tumors. In Bethesda Handbook of Clinical Oncology. In press. Duffy A, Heery CR, Greten TF. Pancreatic Cancer. In Bethesda Handbook of Clinical Oncology. In press. GulleyJL, Madan RA, Heery CR. Therapeutic vaccines and immunotherapy in castrationresistant prostate cancer. Am Soc Clin Oncol Educ Book. 2013; 2013: Schlom J, Madan RA, Bilusic M, Heery CR, Hodge JW, Gulley JL. Immune Targeting of 4

5 Prostate Cancer. ASCO Education Book Heery CR, Bilusic M, Madan R. Emerging treatment strategies for metastatic prostate cancer: The next step forward. In Emerging Cancer Therapeutics: Prostate Cancer Dec. Olivier Mir, William Dahut, Francois Goldwasser, and Christopher Heery. Topoisomerase II Inhibitors: Current Use and Prospects. In DNA Topoisomerases and Cancer. Pub 2012; Recent/Upcoming Presentations: Heery CR. New Approaches in Cancer Immunotherapy. National Institute of Biomedical Imaging and Bioengineering Seminar. September 24, Heery CR. NCI Experience Using Yeast-brachyury Vaccine (GI-6301) in Patients with Advanced Chordoma Connective Tissue Oncology Society Annual Meeting. October 17, Heery CR. Opportunities for Immunotherapy Interventions in Gastrointestinal Malignancies. International Society of Gastrointestinal Oncology Annual Meeting. October 24, Abstracts: Madan RA, Hakim F, Jochems C, Heery CR, O Sullivan GC, Singh H, Surolia I, Tsang KY, Gress R, Schlom J, Gulley J. Impact of Androgen Deprivation Therapy on the Thymus and the Production of Naïve T-cells. Accepted, SITC Annual Meeting Grenga I, Donahue RN, Kim PS, Dempsy B, Gulley JL, Heery CR, Madan RA, Schlom J, Farsaci B. Calculation of an immunoscore based on extensive flow cytometry analysis of PBMCs from metastatic breast cancer patients treated with docetaxel alone or in combination with vaccine. J Clin Oncol 31, 2013 (suppl 26; abstr 31) ASCO Breast Cancer Symposium. Madan RA, Singh NK, Gramza AW, Fojo A, Heery CR, Kim JW, McMahon S, Rauckhorst M, King TH, Apelian D, Schlom J, Gulley JL. A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer. J Clin Oncol 31, 2013 (suppl; abstr TPS3127) ASCO Annual Meeting Singh NK, Kim JW, Heery CR, Dahut WL, Couvillon A, Rauckhorst M, McMahon S, Schlom J, Fojo A, Arlen PM, Gulley JL, Madan RA. A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA TRICOM, in metastatic, castration resistant prostate cancer. J Clin Oncol 31, 2013 (suppl; abstr TPS5104) ASCO Annual Meeting Kim JW, Marte JL, Singh NK, Heery CR, Madan RA, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Kantoff PW, Gulley JL. Safety profile of recombinant poxviral TRICOM vaccines. J Clin Oncol 31, 2013 (suppl; abstr e16036) ASCO Annual Meeting. C. Heery, R. Madan, M. Bilusic, J. Kim, N. Singh, M. Rauckhorst, S. Steinberg, W. Dahut, C. Chen, R. DiPaola, M. Stein, W. Stadler, D. Panicali, J. Hodge, J. Schlom, J. Gulley. A phase 2 randomized clinical trial of Samarium-153 EDTMP (Sm-153) +/- PSA-TRICOM vaccine in metastatic castration resistant prostate cancer (mcrpc) after docetaxel. GU ASCO Meeting,

6 Gulley JL, Madan RA, Stein WD, Wilkerson J, Dahut WL, Heery CR, Schlom J, Wilding G, DiPaola RS. Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. J Clin Oncol 31, 2013 (suppl 6; abstr 57) ASCO Genitournary Cancers Symposium. Kim JW, Marte JL, Bilusic M, Singh NK, Heery CR, Madan RA, Pazdur M, McMahon S, Rauckhorst M, Schlom J, Gulley JL. Safety profile of poxviral vaccines: NCI experience. J Clin Oncol 31, 2013 (suppl 6; abstr 85) Genitourinary Cancers Symposium. C. Heery, N. Ibrahim, R. Madan, M. Mohebtash, P. Arlen, M. Bilusic, J. Kim, N. Singh, S. McMahon, S. Hodge, S. Steinberg, J. Schlom, J. Hodge, J. Gulley. A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-, MUC1-TRICOM. Poster Presentation, San Antonio Breast Cancer Symposium C. Heery, N. Ibrahim, R. Madan, M. Mohebtash, P. Arlen, M. Bilusic, J. Kim, N. Singh, S. McMahon, S. Hodge, S. Steinberg, J. Schlom, J. Hodge, J. Gulley. A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-, MUC1-TRICOM. Poster Discussion, ESMO Annual Meeting, C.R. Heery, R.A. Madan, M. Bilusic, J.W. Kim, N.K. Singh, M. Rauckhorst, C. Chen, W.L. Dahut, W.M. Stadler, R.S. DiPaola, M.N. Stein, J.W. Hodge, J. Schlom, J.L.Gulley. Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA- TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. J Clin Oncol 30, 2012 (suppl; abstr 2526). Poster Presentation at ASCO Annual Meeting, Merit Award. Kim JW, Heery CR, Bilusic M, Singh NK, Madan RA, Sabzevari H, Schlom J, Gulley JL. Firstin-human phase I trial of NHS-IL12 in advanced solid tumors. J Clin Oncol 30, 2012 (suppl; abstr TPS2617) ASCO Annual Meeting. Marshall J, Hwang JJ, Pishvaian MJ, He AR, Weiner LM, Sandene EK, Gulley JL, Heery CR, Schlom J, Speyer S, Richman J, Ferraro J, Coeshott C, Cohn A, Appelian D, Rodell TC. A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer. J Clin Oncol 30, 2012 (suppl; abstr TPS3638) ASCO Annual Meeting. M. Bilusic, J.L. Gulley, J.W. Hodge, K.Y. Tsang, P. M. Arlen, C.R. Heery, M. Rauckhorst, S. McMahon, C. Intrivici, D. Poole, C. Jochems, J. Schlom, R.A. Madan. A phase I trial of a yeastbased therapeutic cancer vaccine targeting CEA expressing cancers. J Clin Oncol 30, 2012 (suppl 4; abstr 458). Gulley J.L., Heery C.R., Bilusic M., Kim J., Stadler W., DiPaola R., Ibrahim N., Madan R. Combining Vaccines with other therapeutics: A strategy to accelerate proof of concept studies? Podium Presentation at Society for Immunotherapy of Cancer Annual Meeting, November C.R. Heery, P. A. Pinto, J. Schlom, K.Y. Tsang, R.A. Madan, D. Poole, M. Vergati, B. Walter Rodriguez, M. Merino, J.L. Gulley. Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer. J Clin Oncol 29: 2011 (suppl; abstr 2530). Poster Presentation ASCO Annual Meeting, Merit Award. R.A. Madan, M. Bilusic, J. W. Hodge, K.Y. Tsang, P. M. Arlen, C.R. Heery, M. Rauckhorst, S. 6

7 McMahon, C. Intrivici, T. A. Ferrara, A. Cohn, D. Apelian, A. Franzusoff, Z. Guo, J. Schlom, J. L. Gulley. A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA. J Clin Oncol 29: 2011 (suppl; abstr 2604). Heery CR, Pinto PA, Schlom J, Tsang KY, Madan RA, Poole D, Vergati M, Walter Rodriguez B, Merino M, Gulley JL. Intraprostatic vaccine administration in patients with locally recurrent prostate cancer. J Clin Oncol 29: 2011 (suppl 7; abstr 141). Schlom J, Madan RA, Bilusic M, Heery CR, Hodge JW, Gulley JL. Immune Targeting of Prostate Cancer. GU ASCO Presentation M. Bilusic, J. L. Gulley, C. Heery, A. B. Apolo, P. M. Arlen, M. Rauckhorst, S. McMahon, W. L. Dahut, J. Schlom, R. A. Madan. A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 29: 2011 (suppl 7; abstr 163). Gulley JL, Madan RA, Heery CR, Bilusic M, Dahut W, Schlom, J. Prostvac: A promising new therapeutic vaccine for Prostate Cancer. Poster presentation, Society of Urologic Oncology, December Madan RA, Bilusic M, Heery CR, Apolo AB, Arlen PM, Dahut WL, Schlom J, Gulley JL. Flutamide with or without a Poxviral-based Therapeutic Cancer Vaccine in patients with nonmetastatic Castration-Resistant Prostate Cancer (CRPC). Poster presentation, Society of Urologic Oncology, December Heery CR, Desjardins A, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Friedman AH, Reardon DA, and Friedman HS. Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma. Journal of Clinical Onocology, ASCO Annual Meeting Proceedings. Vol 24, No 18S (June 20 Supplement), 2006: Peer Reviews: Reviewed manuscript for: Independent Cancer Research Human Vaccines and Immunotherapeutics Expert Reviews of Vaccines Cancer With Mentor ( ) Jounral of Clinical Oncology (Dr. James Gulley) Journal of Oncology (Dr. James Gulley) Cancer (Dr. James Gulley) Prostate Cancer and Prostatic Diseases (Dr. James Gulley) Cancer Immunology Immunotherapy (Dr. Jeffrey Schlom) Technology in Cancer Research and Treatment (Dr. Ravi Madan) The Oncologist (Dr. William Dahut) Grant Reviews Vaccine Treatment and Evaluation Unit (VTEU) Review Committee 2013 Prostate Cancer UK (2013) 7

8 8

9 Memberships/Societies: Member, American Society of Clinical Oncology Member, Society for Immunotherapy of Cancer Committees: NIH Committees: Medical Oncology Branch Representative, Clinical Fellowship Committee Representative, Quality Assessment Committee, 2011-present Reviewer, Neurosurgery Residency Training Program Internal Review, NIH, April 25, 2011 Member, CCR Safety Monitoring Committee (2013-present) Member, CRIS Prescriber Committee (2013-present) Chair, Medical Oncology Service Website Committee (2013-present) Chordoma Foundation Member, Medical Advisory Board, 2014-present 9